257 related articles for article (PubMed ID: 28035063)
21. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
22. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
23. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Nakatsura T; Yoshitake Y; Senju S; Monji M; Komori H; Motomura Y; Hosaka S; Beppu T; Ishiko T; Kamohara H; Ashihara H; Katagiri T; Furukawa Y; Fujiyama S; Ogawa M; Nakamura Y; Nishimura Y
Biochem Biophys Res Commun; 2003 Jun; 306(1):16-25. PubMed ID: 12788060
[TBL] [Abstract][Full Text] [Related]
24. Diffuse and canalicular patterns of glypican-3 expression reflect malignancy of hepatocellular carcinoma.
Kawaida M; Yamazaki K; Tsujikawa H; Fukuma M; Abe Y; Kitago M; Shinoda M; Kitagawa Y; Sakamoto M
Pathol Int; 2019 Mar; 69(3):125-134. PubMed ID: 30729617
[TBL] [Abstract][Full Text] [Related]
25. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.
Pan C; Wang X; Chen W; Tao C; Xu X; Jin L; Chen Y; Zhu L; Zhou L; Pan Z
Med Oncol; 2015 Jan; 32(1):359. PubMed ID: 25432695
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.
Li J; Gao JZ; Du JL; Wei LX
World J Gastroenterol; 2014 May; 20(20):6336-44. PubMed ID: 24876756
[TBL] [Abstract][Full Text] [Related]
27. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis.
Zhang J; Zhang M; Ma H; Song X; He L; Ye X; Li X
Medicine (Baltimore); 2018 Jun; 97(24):e11130. PubMed ID: 29901640
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis.
Xiao WK; Qi CY; Chen D; Li SQ; Fu SJ; Peng BG; Liang LJ
BMC Cancer; 2014 Feb; 14():104. PubMed ID: 24548704
[TBL] [Abstract][Full Text] [Related]
31. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
32. Expression of Glypican 3 in low and high grade urothelial carcinomas.
Aydin O; Yildiz L; Baris S; Dundar C; Karagoz F
Diagn Pathol; 2015 Apr; 10():34. PubMed ID: 25896897
[TBL] [Abstract][Full Text] [Related]
33. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
34. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma.
Lee HJ; Yeon JE; Suh SJ; Lee SJ; Yoon EL; Kang K; Yoo YJ; Kim JH; Seo YS; Yim HJ; Byun KS
Gut Liver; 2014 Mar; 8(2):177-85. PubMed ID: 24672660
[TBL] [Abstract][Full Text] [Related]
36. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
37. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
[TBL] [Abstract][Full Text] [Related]
38. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.
Hagag NA; Ali YBM; Elsharawy AA; Talaat RM
J Gastrointest Cancer; 2020 Mar; 51(1):234-241. PubMed ID: 31028536
[TBL] [Abstract][Full Text] [Related]
39. Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma.
Gong L; Wei LX; Ren P; Zhang WD; Liu XY; Han XJ; Yao L; Zhu SJ; Lan M; Li YH; Zhang W
PLoS One; 2014; 9(1):e87120. PubMed ID: 24498024
[TBL] [Abstract][Full Text] [Related]
40. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma.
Takai H; Kato A; Kato C; Watanabe T; Matsubara K; Suzuki M; Kataoka H
Liver Int; 2009 Aug; 29(7):1056-64. PubMed ID: 19141032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
